• 1
    Sirohi B,Powles R. Multiple myeloma. Lancet. 2004; 363: 875887.
  • 2
    Lenhoff S,Hjorth M,Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000; 95: 711.
  • 3
    Attal M,Harousseau JL,Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349: 24952502.
  • 4
    Attal M,Harousseau JL,Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 9197.
  • 5
    Durie BG. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma. 2005; 6: 181190.
  • 6
    Sherman AC,Simonton S,Latif U,Spohn R,Tricot G. Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant. 2004; 33: 955962.
  • 7
    Chapko MK,Syrjala KL,Schilter L,Cummings C,Sullivan KM. Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant. 1989; 4: 181186.
  • 8
    Catley L,Anderson K. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J. 2004; 5: 923.
  • 9
    Leger CS,Bredeson C,Kearns B,Bence-Bruckler I,Atkins H,Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant. 2000; 6(2A): 204210.
  • 10
    Fermand JP,Katsahian S,Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005; 23: 92279233.
  • 11
    Levy V,Katsahian S,Fermand JP,Mary JY,Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore). 2005; 84: 250260.
  • 12
    Fife BL,Huster GA,Cornetta KG,Kennedy VN,Akard LP,Broun ER. Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol. 2000; 18: 15391549.
  • 13
    Hjermstad MJ,Evensen SA,Kvaloy SO,Fayers PM,Kaasa S. Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study. J Clin Oncol. 1999; 17: 706718.
  • 14
    Andrykowski MA,Bishop MM,Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol. 2005; 23: 599608.
  • 15
    Wettergren L,Langius A,Bjorkholm M,Bjorvell H. Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation—a prospective study. Bone Marrow Transplant. 1997; 20: 497502.
  • 16
    Lee SJ,Fairclough D,Parsons SK, et al. Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol. 2001; 19: 242252.
  • 17
    Syrjala KL,Langer SL,Abrams JR,Storer BE,Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005; 23: 65966606.
  • 18
    Chao NJ,Tierney DK,Bloom JR, et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood. 1992; 80: 825830.
  • 19
    Andrykowski MA,Carpenter JS,Greiner CB, et al. Energy level and sleep quality following bone marrow transplantation. Bone Marrow Transplant. 1997; 20: 669679.
  • 20
    McQuellon RP,Russell GB,Rambo TD, et al. Quality of life and psychological distress of bone marrow transplant recipients: the 'time trajectory' to recovery over the first year. Bone Marrow Transplant. 1998; 21: 477486.
  • 21
    Kopp M,Schweigkofler H,Holzner B, et al. Time after bone marrow transplantation as an important variable for quality of life: results of a cross-sectional investigation using 2 different instruments for quality-of-life assessment. Ann Hematol. 1998; 77(1–2): 2732.
  • 22
    Cleeland CS,Mendoza TR,Wang XS, et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer. 2000; 89: 16341646.
  • 23
    Anderson KO,Giralt SA,Mendoza TR, et al. Symptom burden in patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2007; 39: 759766.
  • 24
    Anderson KG,Giralt SA,Neumann JL, et al. Symptom assessment following autologous transplantation: relation of symptom severity to laboratory measures. American Society of Hematology 45th Annual Meeting, San Diego, California, December 6–9, 2003.
  • 25
    Anderson K. Symptom assessment following autologous transplantation: relation of symptom severity to laboratory measures. American Society of Hematology 45th Annual Meeting, San Diego, California, December 6–9, 2003.
  • 26
    Alamo J,Shahjahan M,Lazarus HM,de Lima M,Giralt SA. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant. 2005; 36: 475479.
  • 27
    Charlson M,Szatrowski TP,Peterson J,Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47: 12451251.
  • 28
    Charlson ME,Pompei P,Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 29
    Sorror ML,Maris MB,Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 38193829.
  • 30
    Sorror ML,Maris MB,Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106: 29122919.
  • 31
    Donato ML,Aleman A,Champlin RE, et al. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma. 2004; 45: 755759.
  • 32
    Giralt S,Bensinger W,Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of 2 phase 1/2 trials. Blood. 2003; 102: 26842691.
  • 33
    Shimoni A,Smith TL,Aleman A, et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001; 27: 821828.
  • 34
    Ferrucci L,Harris TB,Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999; 47: 639646.
  • 35
    Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002; 2: 862871.
  • 36
    Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol. 2005; 28: 177186.
  • 37
    Wang XS,Giralt SA,Warneke CL, et al. Mixed effects modeling of the relationship of cytokines and symptom severity in patients during the first 30 days of autologous BMT [abstract]. International Society for Quality of Life Research Symposium-Stating the Art: Advancing Outcomes Research Methodology and Clinical Applications. Boston, Massachusetts, June 27–29, 2004.
  • 38
    Rossi JF,Fegueux N,Lu ZY, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 2005; 36: 771779.
  • 39
    Bataille R,Barlogie B,Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995; 86: 685691.
  • 40
    Aaronson NK,Ahmedzai S,Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 41
    Cella DF,Tulsky DS,Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570579.